9 May 2024 • Researchers examined the impact of novel antihyperglycemic drugs on asthma exacerbation risk among patients with type 2 diabetes and asthma.

While dipeptidyl peptidase-4 inhibitors (DPP-4 Is) and glucagon-like peptidase 1 receptor agonists (GLP-1 RAs) were associated with higher rates of exacerbations requiring systemic corticosteroids compared to metformin, sodium glucose co-transporter-2 inhibitors (SGLT-2 Is) demonstrated comparable asthma control to metformin.

These findings underscore the potential of SGLT-2 Is as a viable treatment option for patients with both type 2 diabetes and asthma.

Source: The Journal of Allergy and Clinical Immunology: In Practice | Read full story